Literature DB >> 18940578

Intravenous gammaglobulin treatment in HIV-1 infection.

Avi Deener1, Ami Mehra, Larry Bernstein, Jenny Shliozberg, Arye Rubinstein.   

Abstract

The two main indications for the use of intravenous gammaglobulin--antibody replacement therapy and immunomodulation--are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940578     DOI: 10.1016/j.iac.2008.06.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  4 in total

Review 1.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

2.  Clinical applications of immunoglobulin: update.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 3.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

4.  Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.

Authors:  Francesco Cinetto; Raffaella Neri; Fabrizio Vianello; Andrea Visentin; Gregorio Barilà; Sabrina Gianese; Alison Lanciarotta; Cinzia Milito; Marcello Rattazzi; Francesco Piazza; Livio Trentin; Renato Zambello; Carlo Agostini; Riccardo Scarpa
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.